C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. (Q34667820)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. |
scientific article |
Statements
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial (English)
Edith A Perez
George W Sledge
Wilma L Lingle
Robert B Jenkins
Anne E Wiktor
Patrick P Bedroske
S Keith Anderson
William R Sukov
Kazunori Kanehira
Beiyun Chen
Xochiquetzal J Geiger
Cathy A Andorfer
Ann E McCullough
Nancy E Davidson
Silvana Martino
Peter A Kaufman
Leila A Kutteh
Julie R Gralow
Lyndsay N Harris
Monica M Reinholz
18 January 2011
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference